| Phase Ib/II Trials of RDA001 in Triple Negative Metastatic Breast Cancer |
NCT01939418 |
National Cancer Center, Korea |
| A study of Lapatinib in combination with Everolimus in patients with Advanced, Triple Negative Breast Cancer |
NCT01272141 |
Emory University Winship Cancer Institute |
| Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant chemotherapy |
NCT02456857 |
M.D. Anderson Cancer Center |
| Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer |
NCT02531932 |
Icahn School of Medicine at Mount Sinai |
| Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer |
NCT02120469 |
City of Hope Medical Center |
| NECTAR Everolimus Plus Cisplatin (-) Breast Cancer (NECTAR) |
NCT01931163 |
The Methodist Hospital System |
| Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancer |
NCT02616848 |
Istituti Ospitalieri di Cremona |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancer (TORCMEK) |
NCT02583542 |
Queen Mary University of London |
